Skip to content

US · DMAA · SHELL COMPANIES

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) intrinsic value and stock valuation

$10.84as of 2026-09-18 · Mkt cap 263.16M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Drugs Made In America Acquisition Corp. Ordinary Shares DCF and intrinsic value

InvestorsCraft values DMAA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DMAA’s statements →

Drugs Made In America Acquisition Corp. Ordinary Shares Graham Number

Graham Number: $8,393,893.25d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Shell Companies New York, NY, US dmaacorp.com

How the business is doing

Fiscal 2025–2024, USD

Revenue
$0.00
20252024
Net income
-$-479M
20252024
Free cash flow
-$-295M
20252024
Total equity
-$-244M
20252024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2024, USD
FYFY
Revenue$0.00$0.00
Operating income-$-2.82T-$-479M
Net income$5.94T-$-479M
EPSd$282.8K-$55.89
Operating cash flow-$-539.19B-$-295M
Capital expenditure$0.00$5M
Free cash flow-$-539.19B-$-295M
Total assets$239.9T$550.8M
Total debt$0.00$662.3M
Net debt-$-6.14B$661M
Total equity$232.6T-$-244M
Cash and short-term investments$6.14B$1.35B
Income statement
FYFY
Revenue$0.00$0.00
Cost of revenue$0.00$0.00
Gross profit$0.00$0.00
Research and development expenses$0.00$0.00
Selling, general and administrative expenses$2.82T$479.7M
Other expenses$0.00$0.00
Operating expenses$2.82T$479.7M
Cost and expenses$2.82T$479.7M
Interest income$8.76T$0.00
Interest expense$0.00$0.00
Depreciation and amortization$0.00$479.7M
Ebitda-$-2.82T-$-279.85B
Operating income-$-2.82T-$-479M
Total other income/expenses, net$8.76T$0.00
Income before tax$5.94T-$-479M
Income tax expense$0.00$0.00
Net income$5.94T-$-479M
Weighted average shares outstanding$21T$8.57T
Weighted average diluted shares outstanding$21T$8.57T
Balance sheet
FYFY
Cash and short-term investments$6.14B$1.35B
Net receivables$0.00$0.00
Inventory$0.00$0.00
Total current assets$12.2B$4.99B
Property, plant and equipment, net$0.00$0.00
Goodwill and intangible assets$0.00$0.00
Long-term investments$0.00$0.00
Total non-current assets$239.9T$545.8M
Total assets$239.9T$550.8M
Accounts payable$222.2B$0.00
Short-term debt$0.00$662.3M
Deferred revenue$0.00$0.00
Total current liabilities$376.2B$795.7M
Long-term debt$0.00$0.00
Deferred revenue, non-current$0.00$0.00
Total non-current liabilities$6.9T$0.00
Capital lease obligations$0.00$0.00
Total liabilities$7.28T$795.7M
Common stock$239.9T$986M
Retained earnings-$-7.27T-$-279M
Accumulated other comprehensive income (loss)$0.00$0.00
Total equity$232.6T-$-244M
Total investments$0.00$0.00
Total debt$0.00$662.3M
Net debt-$-6.14B$661M
Cash flow statement
FYFY
Net income$3.97T-$-479M
Depreciation and amortization$0.00$0.00
Stock-based compensation$0.00$0.00
Change in working capital$138.9B$132.5M
Accounts receivable$0.00$0.00
Inventory$0.00$0.00
Accounts payable$144.9B$0.00
Net cash provided by operating activities-$-539.19B-$-172.27B
Investments in property, plant and equipment$0.00$0.00
Acquisitions, net$0.00$0.00
Net cash used for investing activities-$-231.15T$0.00
Common stock issued$232.1T-$-328.6B
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$231.7T$173.6B
Net change in cash$4.79B$1.35B
Cash at end of period$6.14B$1.35B
Operating cash flow-$-539.19B-$-295M
Capital expenditure$0.00$5M
Free cash flow-$-539.19B-$-295M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Drugs Made In America Acquisition Corp. Ordinary Shares

        Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.

        CEO
        Roger Bendelac
        Employees
        2
        Beta
        0.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)?

        InvestorsCraft does not currently publish an intrinsic value for DMAA. How the IC value is calculated.

        Is DMAA undervalued?

        InvestorsCraft does not publish an undervaluation signal for DMAA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.